Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-IPF: LYT-100 versus pirfenidone in idiopathic pulmonary fibrosis
NL-OMON61627Phase 3Not yet recruiting
- Sponsor
- PureTech Health
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of deupirfenidone and pirfenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by PureTech Health. Primary endpoint: Absolute change in forced vital capacity. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
deupirfenidonepirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON61627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61627.